logo
Plus   Neg
Share
Email

Roche Reports Positive Data From Phase III IMpower110 Study With Tecentriq

Roche (RHHBY.PK) said a Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine in advanced non-squamous and squamous non-small cell lung cancer met its primary endpoint in an interim analysis showing that Tecentriq monotherapy demonstrated a statistically significant overall survival. Roche said it will now submit the data to global health authorities, including the FDA and EMA.

Also, the company announced that a full pivotal phase III study to treat neuromyelitis optica spectrum disorder showed that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google on Wednesday announced new restrictions on political advertisers around the world. The company has joined Twitter in revising its political ad rules ahead of the election season British luxury car giant Aston Martin unveiled its first SUV at an event in Los Angeles and at a simultaneous event in Beijing. The DBX SUV comes with an aluminium body with a typical Aston Martin grille flanked by LED headlights with LED DRLs. "I can't emphasize enough how incredibly exciting... Google has rolled out an audio news service for Google Assistant, called 'Your News Update,' which will read out a user's customized news feed. According to the tech giant, 'Your News Update' is a smarter way to listen to the news hosted by the Google Assistant. The customized news feed will deliver stories from a variety of media partners, including CBS, Politico, Fox News and CNN.
Follow RTT
>